608 related articles for article (PubMed ID: 34795004)
21. CD155/TIGIT signaling regulates the effector function of tumor-infiltrating CD8+ T cell by NF-κB pathway in colorectal cancer.
Li S; Ding J; Wang Y; Wang X; Lv L
J Gastroenterol Hepatol; 2022 Jan; 37(1):154-163. PubMed ID: 34734434
[TBL] [Abstract][Full Text] [Related]
22. CD155/TIGIT, a novel immune checkpoint in human cancers (Review).
Liu L; You X; Han S; Sun Y; Zhang J; Zhang Y
Oncol Rep; 2021 Mar; 45(3):835-845. PubMed ID: 33469677
[TBL] [Abstract][Full Text] [Related]
23. The spatial coexistence of TIGIT/CD155 defines poorer survival and resistance to adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Ma H; Chen X; Mo S; Mao X; Chen J; Liu Y; Lu Z; Yu S; Chen J
Theranostics; 2023; 13(13):4601-4614. PubMed ID: 37649613
[No Abstract] [Full Text] [Related]
24. TOX-expressing terminally exhausted tumor-infiltrating CD8
Han HS; Jeong S; Kim H; Kim HD; Kim AR; Kwon M; Park SH; Woo CG; Kim HK; Lee KH; Seo SP; Kang HW; Kim WT; Kim WJ; Yun SJ; Shin EC
Cancer Lett; 2021 Feb; 499():137-147. PubMed ID: 33249194
[TBL] [Abstract][Full Text] [Related]
25. The immune checkpoint TIGIT/CD155 promotes the exhaustion of CD8 + T cells in TNBC through glucose metabolic reprogramming mediated by PI3K/AKT/mTOR signaling.
Huang M; Yu X; Wang Q; Jiang Z; Li X; Chen W; Song C
Cell Commun Signal; 2024 Jan; 22(1):35. PubMed ID: 38216949
[TBL] [Abstract][Full Text] [Related]
26. Combining TIGIT blockade with IL-15 stimulation is a promising immunotherapy strategy for lung adenocarcinoma.
Luo B; Sun Y; Zhan Q; Luo Y; Chen Y; Fu T; Yang T; Ren L; Xie Z; Situ X; Liu B; Tang K; Ke Z
Clin Transl Med; 2024 Jan; 14(1):e1553. PubMed ID: 38279870
[TBL] [Abstract][Full Text] [Related]
27. Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.
Ascierto PA; Agarwala S; Botti G; Cesano A; Ciliberto G; Davies MA; Demaria S; Dummer R; Eggermont AM; Ferrone S; Fu YX; Gajewski TF; Garbe C; Huber V; Khleif S; Krauthammer M; Lo RS; Masucci G; Palmieri G; Postow M; Puzanov I; Silk A; Spranger S; Stroncek DF; Tarhini A; Taube JM; Testori A; Wang E; Wargo JA; Yee C; Zarour H; Zitvogel L; Fox BA; Mozzillo N; Marincola FM; Thurin M
J Transl Med; 2016 Nov; 14(1):313. PubMed ID: 27846884
[TBL] [Abstract][Full Text] [Related]
28. TIGIT-CD155 Interactions in Melanoma: A Novel Co-Inhibitory Pathway with Potential for Clinical Intervention.
Mahnke K; Enk AH
J Invest Dermatol; 2016 Jan; 136(1):9-11. PubMed ID: 26763417
[TBL] [Abstract][Full Text] [Related]
29. GITR and TIGIT immunotherapy provokes divergent multicellular responses in the tumor microenvironment of gastrointestinal cancers.
Sathe A; Ayala C; Bai X; Grimes SM; Lee B; Kin C; Shelton A; Poultsides G; Ji HP
Genome Med; 2023 Nov; 15(1):100. PubMed ID: 38008725
[TBL] [Abstract][Full Text] [Related]
30. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
31. CD155 in tumor progression and targeted therapy.
Zhan M; Zhang Z; Zhao X; Zhang Y; Liu T; Lu L; Li XY
Cancer Lett; 2022 Oct; 545():215830. PubMed ID: 35870689
[TBL] [Abstract][Full Text] [Related]
32. PET Imaging of TIGIT Expression on Tumor-Infiltrating Lymphocytes.
Shaffer T; Natarajan A; Gambhir SS
Clin Cancer Res; 2021 Apr; 27(7):1932-1940. PubMed ID: 33408249
[TBL] [Abstract][Full Text] [Related]
33. Immune Exhaustion of T Cells in Alveolar Echinococcosis Patients and Its Reversal by Blocking Checkpoint Receptor TIGIT in a Murine Model.
Zhang C; Lin R; Li Z; Yang S; Bi X; Wang H; Aini A; Zhang N; Abulizi A; Sun C; Li L; Zhao Z; Qin R; Li X; Li L; Aji T; Shao Y; Vuitton DA; Tian Z; Wen H
Hepatology; 2020 Apr; 71(4):1297-1315. PubMed ID: 31410870
[TBL] [Abstract][Full Text] [Related]
34. TIGIT-Fc alleviates acute graft-versus-host disease by suppressing CTL activation via promoting the generation of immunoregulatory dendritic cells.
Zhang D; Hu W; Xie J; Zhang Y; Zhou B; Liu X; Zhang Y; Su Y; Jin B; Guo S; Zhuang R
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):3085-3098. PubMed ID: 29960041
[TBL] [Abstract][Full Text] [Related]
35. TIGIT is Frequently Expressed in the Tumor Microenvironment of Select Lymphomas: Implications for Targeted Therapy.
Libert D; Zhao S; Younes S; Mosquera AP; Bharadwaj S; Ferreira C; Natkunam Y
Am J Surg Pathol; 2024 Mar; 48(3):337-352. PubMed ID: 38148663
[TBL] [Abstract][Full Text] [Related]
36. PD-1 and TIGIT coexpressing CD8 + CD103 + tissue-resident memory cells in endometrial cancer as potential targets for immunotherapy.
Jiang F; Mao M; Jiang S; Jiao Y; Cao D; Xiang Y
Int Immunopharmacol; 2024 Jan; 127():111381. PubMed ID: 38150880
[TBL] [Abstract][Full Text] [Related]
37. TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
Ge Z; Peppelenbosch MP; Sprengers D; Kwekkeboom J
Front Immunol; 2021; 12():699895. PubMed ID: 34367161
[TBL] [Abstract][Full Text] [Related]
38. Self-delivery of TIGIT-blocking scFv enhances CAR-T immunotherapy in solid tumors.
Yang F; Zhang F; Ji F; Chen J; Li J; Chen Z; Hu Z; Guo Z
Front Immunol; 2023; 14():1175920. PubMed ID: 37359558
[TBL] [Abstract][Full Text] [Related]
39. CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8
Braun M; Aguilera AR; Sundarrajan A; Corvino D; Stannard K; Krumeich S; Das I; Lima LG; Meza Guzman LG; Li K; Li R; Salim N; Jorge MV; Ham S; Kelly G; Vari F; Lepletier A; Raghavendra A; Pearson S; Madore J; Jacquelin S; Effern M; Quine B; Koufariotis LT; Casey M; Nakamura K; Seo EY; Hölzel M; Geyer M; Kristiansen G; Taheri T; Ahern E; Hughes BGM; Wilmott JS; Long GV; Scolyer RA; Batstone MD; Landsberg J; Dietrich D; Pop OT; Flatz L; Dougall WC; Veillette A; Nicholson SE; Möller A; Johnston RJ; Martinet L; Smyth MJ; Bald T
Immunity; 2020 Oct; 53(4):805-823.e15. PubMed ID: 33053330
[TBL] [Abstract][Full Text] [Related]
40. DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy.
Niebel D; Fröhlich A; Zarbl R; Fietz S; de Vos L; Vogt TJ; Dietrich J; Sirokay J; Kuster P; Saavedra G; Ramírez Valladolid S; Hoffmann F; Strieth S; Landsberg J; Dietrich D
Clin Epigenetics; 2022 Apr; 14(1):50. PubMed ID: 35410311
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
